Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Feb 08, 2024 7:02pm
124 Views
Post# 35871301

RE:RE:RE:RE:RE:RE:RE:RE:RE:so far so good

RE:RE:RE:RE:RE:RE:RE:RE:RE:so far so goodAzaak,

MC and BT before him have been trying to sell this company for more than 15 years. 

Trouble is, of the forty(ish) tirals they've run, 80% of them failed and the few that showed promise were borderline. 

There is nothing to sell.

MC's only hope for personal gain at this time is to somehow raise another year's worth of cash and continue to collect his salary. The only way he can do this is to over-promise and deceptively suggest that a P3 trial in BC is close (hint, it's not going to happen) and also claim that Roche is collaborating with ONC on a P3 in Pancreatic cancer due to begin enrollment this summer (hint, it's not going to happen).

MC can continue this game indefinitely so long as there are "investors" like you who are willing to part with thier money. It's been working for 25 years, so why not 25 more?

Failed trials include but are not limtied to:

Lung
Prostrate
Ovarian
Melanoma
Head and Neck
Bladder
Brain
Sarcoma
Multple Myeloma
Youth - unspecified solid tumours

Note, many of the above are multiple failed incarnations with different variations of disease and/or combo therapy.

Marginal results include:

Breast
Pancreatic
Colorectal

The only indication that truly has even the slightest chance of ever progressing to a P3 is pancreatic.

But this will never happen under MC's leadership because he does not have the skills to manage a large P3 and neither does he have the ability to successfully partner with a BP. 








<< Previous
Bullboard Posts
Next >>